This session is focused on examining the choke points of label creation and execution. Virtually all studies have an international component, what methodologies and technologies can be leveraged to streamline an already intricate process? This session will examine an exciting new eLabel initiative and communicate what TransCelerate is doing to assist with industry uptake and influencing health authorities. In addition this session will focus on the future or randomization and trial supply management and understanding the shift to self-service, configurable tools. This session will review industry trends and approaches and benefits to moving your organization towards the future with RTSM capabilities.
Learning Objective : - Understand the options and benefits of utilizing eLabeling to enhance site efficiency and enhance patient centricity.
- Discuss approaches, considerations when planning a study, and potential add-on technologies which can further improve productivity at sites.
- Describe some of the misconceptions around the near-term viability for an eLabel solution.
Uncorking the Bottleneck in Labeling for Investigational Medicinal Products in Multicultural Clinical Trials
Transperfect, United States
The Near-Term Viability and Benefits of eLabels for Clinical, Sites, and Patients
Hans O. Von Steiger
Director/Team Leader, Clinical Strategy and Management
Pfizer Inc, United States
The Future of Randomization and Trial Supply Management
Jennifer Bush, MS
Director, Life Sciences Product Strategy
Oracle, United States